Skip to main content
SpringerLink
Log in

Antitumor activity of imidazolium-bisimidazole-tetrachlororuthenate (III)

A representative of a new class of inorganic antitumor agents

  • Short Communication
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Summary

The antitumor activity of imidazolium-bisimidazole-tetrachlororuthenate (III) against the P388 leukemia and against the B16 melanoma was investigated.

The test compound showed high activity against these tumor models. The tumor inhibiting effect was in the range or better than the effects of the compounds cyclophosphamide, cisplatin, or 5-fluorouracil, which were tested as positive controls.

The effective substance is a new, water soluble, anionic, nitrogen-heterocyclic coordinated, ruthenium species, exhibiting antitumor activity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Berger MR, Bischoff H, Hermanek P, Schmähl D (1984) Biological characterization and chemotherapy of autochthonous colorectal tumors in rats. In: Klein HO (ed) Advances in the chemotherapy of gastrointestinal cancer. Perimed-Fachbuch-Verlagsgesellschaft, Erlangen, pp 75–81

    Google Scholar 

  • Clarke MJ (1980) Oncological implications of the chemistry of ruthnium. In: Sigel H (ed) Metal ions in biological systems volume 11, metal complexes as anticancer agents. Marcel Dekker, Inc., Basel, New York, pp 231–276

    Google Scholar 

  • Cleare MJ, Hydes PC (1980) Antitumor properties of metal complexes. In: Sigel H (ed) Metal ions in biological systems volume II, metal complexes as anticancer agents. Marcel Dekker, Inc., Basel, New York, pp 1–56

    Google Scholar 

  • Keller HJ, Keppler BK, Schmähl D (1982) Antitumor activity of cis-dihalogenobis(1-phenyl-1,3-butanedionato)-titanium(IV) compounds against Walker 256 carcinosarcoma. Drug Res 8:806–807

    Google Scholar 

  • Keppler BK, Diez A, Seifried V (1985) Antitumor activity of phenyl substituted dihalogenobis(1-phenyl-1,3-butanedionato)titanium-(IV) compounds. Drug Res 35(II) 12:1832–1836

    Google Scholar 

  • Kralik F, Vrestal J (1960) Komplexverbindungen des Rutheniums mit fünfzähligen heterocyclischen Basen II. Reaktionen des Ruthenium(III)-Chlorids mit Pyrazol und Imidazol. Militärische Akademie “A. Zápotocký”, Brno, 26:1298–1304

    Google Scholar 

  • Osieka R, Schmidt CG (1979) Cis-diamminedichloroplatin(II). Clin Wochenschr 57:1249–1258

    Google Scholar 

  • Prestayko AW, Crooke ST, Carter SK (1980) Cisplatin current status and new developments. Academic Press, Inc., New York

    Google Scholar 

  • Rosenberg B, VanCamp L (1969) Platinum compounds: a new class of potent antitumor agents. Nature 222:385–386

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Anorganisch-Chemisches Institut der Universität, Im Neuenheimer Feld 270, D-6900, Heidelberg, Federal Republic of Germany

    B. K. Keppler & W. Rupp

Authors
  1. B. K. Keppler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. Rupp
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Dedicated to Professor Dietrich Schmähl on the occasion of his 60th birthday

Rights and permissions

Reprints and permissions

About this article

Cite this article

Keppler, B.K., Rupp, W. Antitumor activity of imidazolium-bisimidazole-tetrachlororuthenate (III). J Cancer Res Clin Oncol 111, 166–168 (1986). https://doi.org/10.1007/BF00400758

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00400758

Key words

Search

Navigation